The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR+) breast cancer: A phase II feasibility study.
Erica L. Mayer
No relevant relationships to disclose
Adrienne Brana Gropper
No relevant relationships to disclose
Nadine M. Tung
No relevant relationships to disclose
Michaela Jane Higgins
No relevant relationships to disclose
Tiffany A. Traina
No relevant relationships to disclose
William Thomas Barry
No relevant relationships to disclose
Eric P. Winer
No relevant relationships to disclose
Harold J. Burstein
No relevant relationships to disclose